Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,479
  • Shares Outstanding, K 23,635
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,000 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.39

Options Overview Details

View History
  • Implied Volatility 132.54% ( +12.40%)
  • Historical Volatility 92.79%
  • IV Percentile 13%
  • IV Rank 5.56%
  • IV High 500.86% on 12/20/24
  • IV Low 110.84% on 05/08/25
  • Put/Call Vol Ratio 10.92
  • Today's Volume 155
  • Volume Avg (30-Day) 166
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 3,665
  • Open Int (30-Day) 2,852

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.28
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.94 +5.60%
on 05/12/25
11.52 -27.21%
on 04/28/25
+0.07 (+0.90%)
since 04/11/25
3-Month
5.87 +42.84%
on 03/04/25
11.52 -27.21%
on 04/28/25
+1.53 (+22.23%)
since 02/12/25
52-Week
4.44 +88.85%
on 12/23/24
11.80 -28.94%
on 11/12/24
+1.99 (+31.02%)
since 05/10/24

Most Recent Stories

More News
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

NVCT : 8.39 (-6.73%)
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

NVCT : 8.39 (-6.73%)
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

NVCT : 8.39 (-6.73%)
Nuvectis Pharma to Participate in the 37th Annual Roth Conference

NVCT : 8.39 (-6.73%)
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

NVCT : 8.39 (-6.73%)
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

NVCT : 8.39 (-6.73%)
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

NVCT : 8.39 (-6.73%)
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

NVCT : 8.39 (-6.73%)
Nuvectis Pharma Announces Proposed Public Offering of Common Stock

NVCT : 8.39 (-6.73%)
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – The American Cancer Society has unveiled its Advances in Oncology – 2024 Research Highlights report,...

ONCY : 0.5385 (+3.72%)
PSNL : 5.10 (+1.19%)
ALXO : 0.4352 (+3.05%)
ONC.TO : 0.74 (+4.23%)
NVCT : 8.39 (-6.73%)
TEM : 62.69 (+2.15%)

Business Summary

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

See More

Key Turning Points

3rd Resistance Point 9.95
2nd Resistance Point 9.46
1st Resistance Point 8.92
Last Price 8.39
1st Support Level 7.89
2nd Support Level 7.40
3rd Support Level 6.86

See More

52-Week High 11.80
Fibonacci 61.8% 8.99
Last Price 8.39
Fibonacci 50% 8.12
Fibonacci 38.2% 7.25
52-Week Low 4.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar